Methadone Versus Morphine for Moderate to Severe Cancer-Related Pain: A Double-Blind Randomized Parallel Group Study
18 Years
70 Years
Both
Neoplasms, Pain
Trial Information
Methadone Versus Morphine for Moderate to Severe Cancer-Related Pain: A Double-Blind Randomized Parallel Group Study
Treatment of cancer pain is based on the World Health Organization (WHO) step ladder
approach to the use of analgesic drugs. Medication potency increases at each step of the WHO
ladder, from nonopioid (step 1; e.g., aspirin and nonsteroidal anti-inflammatory drugs)
through weak opioids (step 2; e.g. codeine) plus a nonopioid to strong opioids (step 3;
e.g., morphine) plus a nonopioid analgesic. Morphine is considered the gold standard for
the treatment of moderate to severe pain, but this is based on level C criteria. Research
has discovered that methadone is a potent opioid that operates at several levels which are
important for pain control. The primary aim is to compare morphine versus methadone as a
first-line analgesic in patients with moderate to severe cancer pain. Patients will be
randomized to receive either oral slow-release morphine (15 mg) every 8 hours and
immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain or oral
methadone 2.5 mg every 8 hours and methadone 2.5 mg every 4 hours as needed for breakthrough
pain. Our hypothesis is that methadone will provide equivalent pain control efficacy after
4 weeks of therapy. We postulate that methadone will be as preferable as morphine as an
analgesic. We will compare the two drugs via adverse effects and compare stability of
analgesia via comparison of the number of breakthrough pain episodes. The study will
attempt to establish equivalency of methadone as a first-line analgesic for moderate to
severe cancer pain.
Inclusion Criteria:
- Must have a telephone
- Age: patient must be 18 years or older and less than 70 years of age
- Life expectancy of 3 months or greater
- No prior use of step-3 opioids (step 2 opioids are allowed)
- Provision of informed consent
- Score of 26 or greater on Mini-Mental Status Exam (MMSE) (to be done by investigator
if there is question about mental status)
- Nonmalignant pain will be excluded; however, if the patient has both malignant and
nonmalignant pain, entry into the trial will be determined by the predominant site of
pain
- Moderate to severe cancer related pain that requires the use of step-3 opioids
- Normal renal function
- There will be no exclusionary criteria based on Karnofsky score
- Must live no more than 1 hour away from clinic
- Patient must have pain severity of 5-7/10 on a 0-10 pain scale
Exclusion Criteria:
- Nursing home patients
- Obvious cognitive dysfunction
- Intractable nausea or vomiting
- A true allergy or intolerance to opioids
- Unstable renal function
- Undergoing therapeutic procedures likely to influence pain during the study period
- Gastrointestinal pathology or surgery that influences absorption of morphine or
methadone
- Must not have had treatment with radiotherapy, chemotherapy or radionuclides in the
last 30 days
- History of drug seeking behavior
- Respiratory compromise
- Treatment with bisphosphonates within the last month
- Use of MAO inhibitors
- Drugs that interfere with CYP34A or CYP2D6
- Drugs that interfere with morphine metabolism
- Retroviral therapies
- Active radiation or antineoplastic therapies
- Hepatic dysfunction
- As judged by the investigator, any evidence of severe or uncontrolled systemic
disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal
disease)
- Evidence of any other significant clinical disorder or laboratory finding that makes
it undesirable for the patient to participate in the study
- Study will exclude women who are pregnant and/or nursing
- Women who are of child bearing potential must have a negative urine pregnancy test
- Patients with a recent substance abuse history will be excluded
- Patients with major depression will be excluded
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
The Primary Outcome Measure is Whether the Patient Had at Least 33% Reduction From the Baseline Visual Numeric Scale Score for Pain at the Time of the Visit.
Outcome Time Frame:
Week 4
Safety Issue:
No
Principal Investigator
Eric E. Prommer, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Mayo Clinic
Authority:
United States: Institutional Review Board
Study ID:
07-003051
NCT ID:
NCT00573937
Start Date:
August 2007
Completion Date:
April 2009
Related Keywords:
- Neoplasms
- Pain
- Neoplasms
- Pain
- Methadone
- Morphine
- Neoplasms
Name | Location |
|---|---|
| Mayo Clinic Arizona | Scottsdale, Arizona 85259 |
